Retinoic acid receptor fusion proteins: friend or foe.


Acute promyelocytic leukemia (APL) is characterized by a block in differentiation of hematopoietic cells at the promyelocytic stage of development. This disease is uniquely sensitive to treatment with pharmacological doses of all-trans retinoic acid (ATRA), and the combination of ATRA with chemotherapy has improved the durable disease-free survival in these… (More)


Cite this paper

@article{Ridder2000RetinoicAR, title={Retinoic acid receptor fusion proteins: friend or foe.}, author={Marleen C Breems-de Ridder and Bernward L{\"o}wenberg and J. A. H. Jansen}, journal={Molecular and cellular endocrinology}, year={2000}, volume={165 1-2}, pages={1-6} }